中文 | English
Return
Total: 7 , 1/1
Show Home Prev Next End page: GO
MeSH:(Macular Degeneration/drug therapy/physiopathology)

1.Single-site Baseline and Short-term Outcomes of Clinical Characteristics and Life Quality Evaluation of Chinese Wet Age-related Macular Degeneration Patients in Routine Clinical Practice.

Li-Li WANG ; Wen-Jia LIU ; Hai-Yun LIU ; Xun XU

Chinese Medical Journal 2015;128(9):1154-1159

2.Assessment of Patient Pain Experience during Intravitreal 27-Gauge Bevacizumab and 30-Gauge Ranibizumab Injection.

Mete GULER ; Burak BILGIN ; Musa CAPKIN ; Ali SIMSEK ; Semsettin BILAK

Korean Journal of Ophthalmology 2015;29(3):190-194

3.Assessment of Patient Pain Experience during Intravitreal 27-Gauge Bevacizumab and 30-Gauge Ranibizumab Injection.

Mete GULER ; Burak BILGIN ; Musa CAPKIN ; Ali SIMSEK ; Semsettin BILAK

Korean Journal of Ophthalmology 2015;29(3):190-194

4.Multifocal Electroretinogram Findings after Intravitreal Bevacizumab Injection in Choroidal Neovascularization of Age-Related Macular Degeneration.

Joo Youn PARK ; Seung Hoon KIM ; Tae Kwann PARK ; Young Hoon OHN

Korean Journal of Ophthalmology 2011;25(3):161-165

5.Predictive Findings of Visual Outcome in Spectral Domain Optical Coherence Tomography after Ranibizumab Treatment in Age-related Macular Degeneration.

Yoon Hyung KWON ; Dong Kyu LEE ; Hyung Eun KIM ; Oh Woong KWON

Korean Journal of Ophthalmology 2014;28(5):386-392

6.Intravitreal Anti-vascular Endothelial Growth Factor for Typical Exudative Age-related Macular Degeneration in Eyes with Good Baseline Visual Acuity.

Young Suk CHANG ; Jung Il HAN ; Su Jin YOO ; Young Ju LEW ; Jae Hui KIM

Korean Journal of Ophthalmology 2014;28(6):466-472

7.Effects of Vitreomacular Traction on Ranibizumab Treatment Response in Eyes with Neovascular Age-related Macular Degeneration.

Kang Hoon LEE ; Hee Seung CHIN ; Na Rae KIM ; Yeon Sung MOON

Korean Journal of Ophthalmology 2015;29(6):396-403

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 7 , 1/1 Show Home Prev Next End page: GO